Natural Vitamin D3 Supplement Supports Year-Round Sufficiency
FORT LAUDERDALE, September 3, 2025 – As daylight dwindles in parts of the northern hemisphere, maintaining adequate vitamin D...
cGxPwire Editor
Advertisement
Andelyn Biosciences Partners with Tern Therapeutics for Late-Stage Manufacturing of AAV Gene Therapy for CLN2 Batten Disease
Andelyn Biosciences, a leading cell and gene therapy CDMO, has partnered with Tern Therapeutics to perform late-stage Process Performance...
AliveDx Submits FDA 510(k) for MosaiQ AiPlex® Vasculitis Assay to Advance Autoimmune Diagnostics
AliveDx, a global in-vitro diagnostics innovator, today announced it has submitted a 510(k) premarket notification to the U.S. Food...
First Patient Dosed in CAR-T Trial Using Synecta T1 Nanoparticles
PHILADELPHIA, September 3, 2025 — The first patient has been dosed in a clinical trial evaluating Synecta™ T1 cell-derived...
Spring Health Joins Workday Wellness to Deliver Precision Mental Health
NEW YORK, September 3, 2025 — Spring Health has officially joined the Workday Wellness Partner Program as a Strategic...
Advertisements
FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
GeneseeqPrime Gains FDA 510(k) Clearance for Tumor Profiling Kit
TORONTO, Sept. 2, 2025 – Geneseeq Technology Inc. announced that its GeneseeqPrime® NGS Tumor Profiling Assay has received 510(k)...
Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations
Nanoscope Therapeutics, a biotechnology company advancing disease-agnostic optogenetic therapies for retinal degenerations, announced a major global regulatory milestone with...
Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
Hoth Therapeutics Advances HT-KIT After Preclinical Breakthrough
NEW YORK, Sept. 2, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, announced encouraging preclinical results...
Advertisement
